Literature DB >> 32249925

The role of B cells in the immunopathogenesis of multiple sclerosis.

Tohid Gharibi1,2,3,4,5, Zohreh Babaloo1,2, Arezoo Hosseini1,2,3,4, Faroogh Marofi1,2, Abbas Ebrahimi-Kalan3,4, Saeed Jahandideh6, Behzad Baradaran1,2.   

Abstract

There is ongoing debate on how B cells contribute to the pathogenesis of multiple sclerosis (MS). The success of B-cell targeting therapies in MS highlighted the role of B cells, particularly the antibody-independent functions of these cells such as antigen presentation to T cells and modulation of the function of T cells and myeloid cells by secreting pathogenic and/or protective cytokines in the central nervous system. Here, we discuss the role of different antibody-dependent and antibody-independent functions of B cells in MS disease activity and progression proposing new therapeutic strategies for the optimization of B-cell targeting treatments.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  B cells; B-cell-depleting therapies; antibodies; multiple sclerosis

Mesh:

Substances:

Year:  2020        PMID: 32249925      PMCID: PMC7370136          DOI: 10.1111/imm.13198

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  161 in total

1.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

Review 2.  Regulatory T Cells: From Discovery to Autoimmunity.

Authors:  Alexandra Kitz; Emily Singer; David Hafler
Journal:  Cold Spring Harb Perspect Med       Date:  2018-12-03       Impact factor: 6.915

3.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

Review 4.  Antibody-independent functions of B cells: a focus on cytokines.

Authors:  Ping Shen; Simon Fillatreau
Journal:  Nat Rev Immunol       Date:  2015-06-12       Impact factor: 53.106

5.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

Authors:  Anne H Cross; Jennifer L Stark; Joanne Lauber; Michael J Ramsbottom; Jeri-Anne Lyons
Journal:  J Neuroimmunol       Date:  2006-08-14       Impact factor: 3.478

6.  Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Authors:  R A Rudick; D L Cookfair; N A Simonian; R M Ransohoff; J R Richert; L D Jacobs; R M Herndon; A M Salazar; J S Fischer; C V Granger; D E Goodkin; J H Simon; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munchsauer; K O'Reilly; R L Priore; R H Whitham
Journal:  J Neuroimmunol       Date:  1999-01-01       Impact factor: 3.478

7.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

Authors:  Y Qin; P Duquette; Y Zhang; P Talbot; R Poole; J Antel
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

8.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

9.  B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses.

Authors:  Judith Fraussen; Nele Claes; Bart Van Wijmeersch; Jack van Horssen; Piet Stinissen; Raymond Hupperts; Veerle Somers
Journal:  Clin Immunol       Date:  2016-10-04       Impact factor: 3.969

10.  Dimethyl fumarate alters B-cell memory and cytokine production in MS patients.

Authors:  Matthew D Smith; Kyle A Martin; Peter A Calabresi; Pavan Bhargava
Journal:  Ann Clin Transl Neurol       Date:  2017-04-17       Impact factor: 4.511

View more
  3 in total

Review 1.  Neutrophils: Underestimated Players in the Pathogenesis of Multiple Sclerosis (MS).

Authors:  Mirre De Bondt; Niels Hellings; Ghislain Opdenakker; Sofie Struyf
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

Review 2.  Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis?

Authors:  Sofia Fernanda Goncalves Zorzella-Pezavento; Luiza Ayumi Nishiyama Mimura; Marina Bonifácio Denadai; William Danilo Fernandes de Souza; Thais Fernanda de Campos Fraga-Silva; Alexandrina Sartori
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

Review 3.  Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies.

Authors:  Agnese Gugliandolo; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.